Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Long-Term Deferred Tax (2016 - 2025)

BioCorRx (BICX) has disclosed Long-Term Deferred Tax for 12 consecutive years, with $13.2 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax changed N/A to $13.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $13.2 million for FY2025, N/A changed from the prior year.
  • Long-Term Deferred Tax hit $13.2 million in Q4 2025 for BioCorRx, up from $10.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $13.2 million in Q4 2025 to a low of $9.8 million in Q4 2021.
  • Historically, Long-Term Deferred Tax has averaged $11.2 million across 3 years, with a median of $10.7 million in 2022.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 35.63% in 2021 and later increased 9.13% in 2022.
  • Year by year, Long-Term Deferred Tax stood at $9.8 million in 2021, then rose by 9.13% to $10.7 million in 2022, then increased by 23.09% to $13.2 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for BICX at $13.2 million in Q4 2025, $10.7 million in Q4 2022, and $9.8 million in Q4 2021.